Growing demand for weight-loss solutions has catapulted pharmaceutical firms like Eli Lilly (LLY) and Novo Nordisk (NVO) into ...

As Amanda Phommachanh, a 45-year-old realtor in Manassas, Virginia, describes it, she was on track with Wegovy to meet her ...

Novo Nordisk’s amycretin shows 22% weight loss over 36 weeks, potentially surpassing Eli Lilly’s Zepbound. Further trials are ...

Shares in Veru fell by nearly half following the news, despite positive results in preserving lean muscle mass.

This year, revolutionary anti-obesity drugs Wegovy and Ozempic (manufactured by Danish drugmaker Novo Nordisk), and Eli Lilly ...

Beyond GLP-1 drugs, healthcare companies are expanding their portfolios with new cancer therapies ... who can’t diet or ...

People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.

CDSCO Panel Approves Eli Lilly's Protocol Amendment Proposal for Antidiabetic Drug Retatrutide study The complaint against Thrive was filed in the district court of Colorado and the complaint against ...

Health-care companies slid after a profit warning from Eli Lilly. Shares of the obesity-drug maker tumbled after ... according to a new report by the Federal Trade Commission.

FILE PHOTO: An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, U.S., December 11, 2023. REUTERS/Brendan McDermid/File Photo · REUTERS / Reuters JPMorgan analyst ...

The new outlook would still mark a 32% jump in revenue from the prior year. Eli Lilly has been racing to meet soaring demand for its diabetes treatment Mounjaro and obesity drug Zepbound ...

Eli Lilly cut its 2024 revenue guidance, saying demand for its obesity and diabetes drugs had not met its lofty expectations. Eli Lilly expects about $3.5 billion in revenue for its diabetes ...